RESUMO
On Jan 20, 2022, in an unprecedented move, the Brazilian Secretary for Science, Technology, and Innovation overrode the Brazilian guideline for COVID-19 outpatient treatment. The guideline was originally demanded by the Ministry of Health, developed by a team of academics, specialists, and health technology analysts, according to GRADE-ADOLOPMENT methodology.1 The guideline, which recommended against the use of drugs without scientific proof of efficacy, such as hydroxychloroquine and ivermectin,2 was finally approved by the National Committee for Health Technology Incorporation (CONITEC) in December, 2021. In the Brazilian public health system, CONITEC has a central role in evaluating and recommending technology implementation on the basis of the scientific paradigms of efficacy, effectiveness, and cost-effectiveness.
